Expertise in
8
conditions

Dr. Vandana G. Abramson

Oncology
Vanderbilt-Ingram Cancer Center
2220 Pierce Ave, 
Nashville, TN 
Accepting New Patients
Offers Telehealth
Expertise in
8
conditions
Vanderbilt-Ingram Cancer Center
2220 Pierce Ave, 
Nashville, TN 

Overview

Vandana Abramson is an Oncologist practicing medicine in Nashville, Tennessee.

Dr. Abramson is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, HER-2 Positive Breast Cancer, and Tissue Biopsy.

She is actively involved in clinical research, co-authoring 102 peer reviewed articles and participating in 14 clinical trials. Dr. Abramson is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in PA

Hospital Affiliations

Vanderbilt University Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
MetLife
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Vanderbilt-Ingram Cancer Center
2220 Pierce Ave, Nashville, TN 37232

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Atezolizumab, Olaparib
Study Phase: Phase 2
A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer
A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2026
Intervention Type: Drug, Procedure
Study Drugs: Trastuzumab, Pertuzumab
Study Phase: Phase 2
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib
The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Other, Biological, Drug
Study Drugs: Trastuzumab Emtansine, Tucatinib
Study Phase: Phase 3
A Phase II Study of Niraparib With Dostarlimab Therapy as Neoadjuvant Treatment for Patients With BRCA-mutated Breast Cancer
A Phase II Study of Niraparib With Dostarlimab Therapy as Neoadjuvant Treatment for Patients With BRCA-mutated Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 13, 2026
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 2
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Enrollment Status: Completed
Publish Date: February 19, 2026
Intervention Type: Drug
Study Drugs: Trastuzumab, Paclitaxel, Trastuzumab emtansine
Study Phase: Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized Phase II Study of Pembrolizumab, an Anti-Programmed Cell Death (PD)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
A Randomized Phase II Study of Pembrolizumab, an Anti-Programmed Cell Death (PD)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
Enrollment Status: Completed
Publish Date: December 22, 2025
Intervention Type: Biological, Drug
Study Drugs: Pembrolizumab, Carboplatin, Trastuzumab
Study Phase: Phase 2
A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients With Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker
A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients With Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker
Enrollment Status: Completed
Publish Date: September 30, 2025
Intervention Type: Drug
Study Drugs: Paclitaxel, Cisplatin
Study Phase: Phase 2
A Phase II Trial of Atezolizumab (Anti-PDL1) With Carboplatin in Patients With Metastatic Triple Negative Breast Cancer
A Phase II Trial of Atezolizumab (Anti-PDL1) With Carboplatin in Patients With Metastatic Triple Negative Breast Cancer
Enrollment Status: Completed
Publish Date: December 12, 2024
Intervention Type: Other, Drug
Study Drugs: atezolizumab, carboplatin
Study Phase: Phase 2
View 9 Less Clinical Trials

102 Total Publications

Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.
Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: July 09, 2026
Similar Doctors
Expertise in
39
conditions
Expertise in
39
conditions
Referral may be required

Tennessee Oncology, PLLC-#412 25th Ave

250 25th Ave N, Ste 412, 
Nashville, TN 
 (1.0 miles away)
615-986-7600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ian Flinn is an Oncologist practicing medicine in Nashville, Tennessee. Dr. Flinn is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Non-Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Flinn is board certified in The American Board Of Internal Medicine - Hematology. Dr. Flinn is currently accepting new patients.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

SCRI Oncology Partners

335 24th Ave N, Ste 200, 
Nashville, TN 
 (0.9 miles away)
615-329-7640
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Erika Hamilton, MD, is an independent medical oncologist and hematologist at Ascension Saint Thomas in Nashville, Tennessee. Dr. Hamilton diagnoses and treats adults with cancer and focuses on managing care during and after chemotherapy, radiation therapy and surgery. Every appointment with Dr. Hamilton starts with a conversation. She takes the time to answer all your questions — big and small. Dr. Hamilton is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, HER2 Negative Breast Cancer, Ovarian Cancer, and HER-2 Positive Breast Cancer. Dr. Hamilton is board certified in The American Board Of Internal Medicine - Medical Oncology. Dr. Hamilton is currently accepting new patients.

Expertise in
31
conditions
Expertise in
31
conditions
Referral may be required

Tennessee Oncology, PLLC-#412 25th Ave

250 25th Ave N, Ste 412, 
Nashville, TN 
 (1.0 miles away)
615-986-7600
Languages Spoken:
English, French, Russian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jesus Berdeja is an Oncologist practicing medicine in Nashville, Tennessee. Dr. Berdeja is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Acute Myeloid Leukemia (AML), and Bone Marrow Aspiration. Dr. Berdeja is board certified in The American Board Of Internal Medicine - Hematology. Dr. Berdeja is currently accepting new patients.

Frequently Asked Questions about Dr. Vandana G. Abramson

How do I make an appointment with Dr. Vandana G. Abramson?

You can book an appointment with Dr. Vandana G. Abramson by calling their office at 615-322-5000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Vandana G. Abramson a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Vandana G. Abramson is classified as an Elite expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Vandana G. Abramson specialize in?

While Dr. Vandana G. Abramson is a Oncology, they have specific expertise in Breast Cancer, Triple-Negative Breast Cancer, and Inflammatory Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Vandana G. Abramson participate in research or clinical trials?

Yes. Dr. Vandana G. Abramson has published 102 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Vandana G. Abramson's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Vandana G. Abramson accept my insurance?

Dr. Vandana G. Abramson accepts most major insurance plans, including Aetna and Alliant Health. We recommend calling the office directly at 615-322-5000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Abramson's expertise for a condition
ConditionClose
View All 15 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile